venBio is a venture capital and private equity firm early and late-stage investment in life science, healthcare, and therapeutics companies that is headquartered in San Francisco, California and was founded in 2011 by Corey Goodman, Kurt con Emter, and Robert Adelman.
As of November 2019 venBio has made 42 investments, has 20 companies in its portfolio, and has made 18 exits. Notable investments made by venBio include: Inbrace, Neurogastrix, Swfit Health Systems, Aeovian Pharmaceuticals, Checkmate Pharmaceuticals, Turning Point Therapeutics, Precision BioSciences, Akero Therapeutics, Oncobiologics, and Corvus Pharmaceuticals.
On May 6, 2016 venBio announced raising $315 million for their second venture capital fund; exceeding its initial target of $250 million. The fund has three strategic limited parters which are Amgen, Merk, and Baxalta, and a group of financial limited partners. At the time of announcing their second fund venBio also announced adding Aaron Royston and Jaume Pons to their investment team. Robert Adelman, the managing partner of venBio, made the following statement regarding the firms second venture capital fund:
We believe our fund model is unique. With the return of Amgen and Baxalta, along with the addition of Merck, the commitment from our Strategic Limited Partners is now larger than ever. Our investment model will remain the same. We continue to seek to finance promising life sciences companies that focus on therapeutics which we believe will make a difference for unmet medical needs.